摘要:
Amorphous atorvastatin calcium having an enhanced stability contains about 2 to about 8 percent by weight water. A process for preparing the amorphous atorvastatin calcium and a packaging system for maintaining the stability are described.
摘要:
The present invention provides processes to prepare atorvastatin calcium Form VI, pharmaceutical compositions comprising atorvastatin calcium Form VI, and processes to prepare said compositions. An aspect of the invention relates to atorvastatin calcium Form VI compositions having enhanced bioavailability when administered orally to humans.
摘要:
A process for preparing atorvastatin calcium Form I, comprising adding a solution comprising atorvastatin calcium and an alcohol to water. Optionally, the water can contain seed crystals of atorvastatin calcium Form I.
摘要:
Intermediate compounds for preparing rosuvastatin are prepared by a process comprising oxidizing hydroxy groups to aldehyde groups, using sodium hypochlorite and 2,2,6,6-tetramethyl piperidinyl oxy free radical (TEMPO) as a catalyst.
摘要:
Intermediate compounds for preparing rosuvastatin are prepared by a process comprising oxidizing hydroxy groups to aldehyde groups, using sodium hypochlorite and 2,2,6,6-tetramethyl piperidinyl oxy free radical (TEMPO) as a catalyst.
摘要:
The present invention relates to novel crystalline forms of atorvastatin calcium and to the methods of their production and isolation. More specifically, the present invention relates to novel Forms VI and VII of R—(R*,R*)]-2(4-fluorophenyl)-B,d dihydroxy-5(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-H-pyrrole-1-heptanoic- acid calcium salt and hydrates thereof and to methods of their preparation.
摘要:
The present patent application relates to a novel crystalline form (Form S) of Carvedilol dihydrogen phosphate and a process for its preparation. It also relates to an improved process for the preparation of Carvedilol dihydrogen phosphate.
摘要:
Amorphous simvastatin is prepared by rapidly removing solvent from a solution comprising simvastatin. The solution can also comprise a pharmaceutically acceptable carrier, to form a dispersion of amorphous simvastatin in the carrier.